GHRH Analog · Peptide

Tesamorelin

Targeted growth-hormone release.

A synthetic GHRH analog that stimulates the pituitary to release growth hormone — supporting visceral-fat reduction, lipid profile, and lean-tissue preservation.

SubcutaneousDaily
Classification
GHRH Analog · Peptide
Administration
Subcutaneous · Daily
About

Releasing the body's own GH.

A synthetic analog of growth hormone-releasing hormone that prompts the pituitary to release GH naturally — preserving the body's feedback loop.

Who this is for
  • Adults addressing stubborn visceral abdominal fat
  • Patients pursuing lean-tissue preservation in aging
  • Anyone seeking metabolic and lipid-profile support
Clinical benefits
1

Visceral Abdominal Fat Reduction

Selectively reduces visceral fat without affecting subcutaneous. Abdominal circumference often softens visibly.

2

Improved Lipid Profile

Decreases total and LDL cholesterol with potential HDL improvement. Cholesterol numbers tend to move favorably.

3

Lean Muscle Support

Elevated endogenous GH supports lean-tissue preservation. Strength and physical capacity feel more sustained.

4

Cognitive & Brain Health

GH-mediated effects may support cognition in older adults. Mental clarity and focus often improve.

5

Physiologic GH Release

Stimulates the body's own GH rather than supplementing. Energy and recovery patterns shift gently.

What to expect — patients often report
WEEKS 1 – 4

Subtle changes; body adjusts to GH-axis activation.

MONTH 2 – 3

Visceral fat changes measurable; composition shifts.

MONTH 6+

Sustained lipid and lean-mass improvements.

The RENEWL Standard
  • Physician-supervised by Thomas Nabity, MD
  • 503A / 503B compounding pharmacy sourcing
  • Pre-protocol labs, body composition, and review
  • 30 / 60 / 90-day follow-up with companion support

Is Tesamorelin right for you?